Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Endologix Inc (ELGX)

Endologix Inc (ELGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,218
  • Shares Outstanding, K 19,172
  • Annual Sales, $ 143,370 K
  • Annual Income, $ -64,760 K
  • 60-Month Beta 0.73
  • Price/Sales 0.04
  • Price/Cash Flow N/A
  • Price/Book 0.08
Trade ELGX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.13
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.87
  • Number of Estimates 2
  • High Estimate -0.78
  • Low Estimate -0.95
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -135.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2200 unch
on 07/15/20
1.1400 -80.70%
on 06/16/20
-0.7450 (-77.20%)
since 06/15/20
3-Month
0.2200 unch
on 07/15/20
1.2600 -82.54%
on 06/09/20
-0.6221 (-73.87%)
since 04/15/20
52-Week
0.2200 unch
on 07/15/20
7.1000 -96.90%
on 07/31/19
-6.2300 (-96.59%)
since 07/15/19

Most Recent Stories

More News
Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States

Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) ("Endologix" or the "Company") today announced the first implant of its recently approved ALTO(R) endograft...

ELGX : 0.2200 (-23.88%)
ELGXQ : 0.0199 (-24.33%)
Delisting of Securities of KemPharm, Inc.; Endologix, Inc.; VIVUS, Inc.; SAExploration Holdings, Inc.; Ascena Retail Group, Inc.; and Global Eagle Entertainment Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of KemPharm, Inc. KemPharm, Inc.'s common stock was suspended on May 21, 2020 and has not traded on Nasdaq since that time....

ASNA : 0.6063 (-15.67%)
ELGX : 0.2200 (-23.88%)
KMPH : 1.0970 (-2.05%)
NDAQ : 127.33 (+0.05%)
SAEX : 0.3000 (-51.61%)
VVUS : 0.4665 (-10.29%)
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

, /PRNewswire/ -- a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: , joining...

ELGX : 0.2200 (-23.88%)
Endologix Announces Departure of CFO and Appointment of Interim CFO

Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO),...

ELGX : 0.2200 (-23.88%)
Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

Endologix(R) Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the...

ELGX : 0.2200 (-23.88%)
Endologix (ELGX) Reports Q1 Loss, Tops Revenue Estimates

Endologix (ELGX) delivered earnings and revenue surprises of -19.40% and 0.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ELGX : 0.2200 (-23.88%)
Endologix: 1Q Earnings Snapshot

IRVINE, Calif. (AP) _ Endologix Inc. (ELGX) on Monday reported a loss of $18.1 million in its first quarter.

ELGX : 0.2200 (-23.88%)
Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

Endologix(R) Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory...

ELGX : 0.2200 (-23.88%)
Endologix Reports First Quarter 2020 Financial Results

Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020....

ELGX : 0.2200 (-23.88%)
Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after...

ELGX : 0.2200 (-23.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Key Turning Points

2nd Resistance Point 0.2999
1st Resistance Point 0.2599
Last Price 0.2200
1st Support Level 0.2000
2nd Support Level 0.1801

See More

52-Week High 7.1000
Fibonacci 61.8% 4.4718
Fibonacci 50% 3.6600
Fibonacci 38.2% 2.8482
Last Price 0.2200
52-Week Low 0.2200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar